Improving Healthcare Access

September is National Sickle Cell Awareness Month, and Aflac, a leader in supplemental insurance sales at U.S. worksites, today announced the company's 2020 annual contribution of $1.5 million to the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta has been earmarked for the hospital's Sickle Cell Disease Program.

Come get a glimpse of how the world can be reimagined toward a much stronger future with your help.

New Hope Middle School officially opened its new Kodiak Calming Cove, a sensory room for children with special needs, recently, and "it'll make a big difference for students to have a safe space they can go into," said Belinda Sloan, the school's principal.

Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.

We’re pleased to announce that based on interim results from our ongoing studies, the Janssen Pharmaceutical Companies of Johnson & Johnson are launching ENSEMBLE, a large-scale, multi-country Phase 3 trial of a single dose of our vaccine candidate.

PYXERA Global’s Reimagining Community Health Systems Challenge ended in September with U.S. Community Health Centers poised to play a stronger role in expanding telehealth services for 30 million low-income patients

While consumers were getting a crash course in supply and demand, the experts at Johnson & Johnson remained confident in their ability to manage or circumvent disruptions so that hospitals, pharmacies and people around the world could continue to get much needed medications, medical devices and other healthcare products.

Together with the support of VF’s product design and development teams, our JanSport® and Eagle Creek® brands have developed a range of new consumer mask choices that are not only fashionable, but produced in an environmentally responsible manner.